Pharvaris (NASDAQ:PHVS) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Pharvaris (NASDAQ:PHVS) from a hold rating to a sell rating in a research report sent to investors on Sunday.

A number of other equities research analysts have also issued reports on the stock. Royal Bank Of Canada started coverage on shares of Pharvaris in a report on Monday, March 9th. They issued an “outperform” rating and a $52.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and an average price target of $42.80.

Pharvaris Stock Down 1.9%

Shares of Pharvaris stock opened at $27.84 on Friday. The firm has a market cap of $1.51 billion, a PE ratio of -8.26 and a beta of -2.58. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.85. The company’s fifty day simple moving average is $27.08 and its two-hundred day simple moving average is $25.48.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new stake in shares of Pharvaris in the 4th quarter worth about $1,536,000. XTX Topco Ltd lifted its position in shares of Pharvaris by 126.1% in the 4th quarter. XTX Topco Ltd now owns 18,568 shares of the company’s stock worth $515,000 after purchasing an additional 10,355 shares during the period. Ikarian Capital LLC lifted its position in shares of Pharvaris by 131.7% in the 4th quarter. Ikarian Capital LLC now owns 486,856 shares of the company’s stock worth $13,510,000 after purchasing an additional 276,691 shares during the period. Virtus Investment Advisers LLC lifted its position in shares of Pharvaris by 66.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock worth $306,000 after purchasing an additional 4,407 shares during the period. Finally, SummitTX Capital L.P. purchased a new stake in shares of Pharvaris in the 4th quarter worth about $634,000.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wedbush raised its price target to $42 and kept an “outperform” rating, implying roughly a 50% upside from current levels — a near-term bullish catalyst from an influential equity shop. Benzinga
• Positive Sentiment: HC Wainwright issued long-range FY2030 estimates calling for EPS of $5.37 and maintains a “Buy” rating with a $60 target — a highly constructive, bullish long-term projection that signals analysts expect strong eventual profitability. MarketBeat
• Neutral Sentiment: Brokerage consensus remains favorable overall — PHVS is reported to have an average rating of “Moderate Buy,” reflecting broad analyst support but varied views on timing and magnitude of upside. American Banking News
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $52 to $51 but left an “outperform” rating in place — a small downgrade in projection that still implies large upside, so its market impact is muted. Benzinga
• Negative Sentiment: Coverage and commentary are questioning whether Phase 3 completion and projected 2025 losses change Pharvaris’ investment narrative; concerns about near-term profitability and how the market will value post‑Phase 3 commercialization are weighing on sentiment. Yahoo Finance

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.